Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 3/2023

28.10.2023 | Review

Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches

verfasst von: Hsuan-Chi Chen, Chuang-Wei Wang, Wu Han Toh, Hua-En Lee, Wen-Hung Chung, Chun-Bing Chen

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Bullous pemphigoid is one of the most common autoimmune bullous diseases occurring primarily in the elderly. Pathogenic autoantibodies against BP180 and BP230 at the dermal–epidermal junction cause subepidermal blisters, erosions, and intense pruritus, all of which adversely affect the patients’ quality of life and may increase their morbidity and mortality. Current systemic treatment options for bullous pemphigoid are limited to corticosteroids and immunosuppressants, which can have substantial side effects on these vulnerable patients that even exceed their therapeutic benefits. Therefore, more precisely, targeting therapies to the pathogenic cells and molecules in bullous pemphigoid is an urgent issue. In this review, we describe the pathophysiology of bullous pemphigoid, focusing on autoantibodies, complements, eosinophils, neutrophils, proteases, and the T helper 2 and 17 axes since they are crucial in promoting proinflammatory environments. We also highlight the emerging therapeutic targets for bullous pemphigoid and their latest discoveries in clinical trials or experimental studies. Further well-designed studies are required to establish the efficacy and safety of these prospective therapeutic options.
Literatur
1.
Baigrie D, Nookala V (2022) Bullous pemphigoid. StatPearls. Treasure Island (FL)
2.
Schmidt E, Della Torre R, Borradori L (2012) Clinical features and practical diagnosis of bullous pemphigoid. Immunol Allergy Clin 32(2):217–232
3.
4.
5.
6.
Chen Y, Wu C, Lin M, Chen T, Liao K, Chen Y et al (2011) Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 165(3):593–599PubMedCrossRef
7.
Langan SM, Groves RW, West J (2011) The relationship between neurological disease and bullous pemphigoid: a population-based case–control study. J Invest Dermatol 131(3):631–636PubMedCrossRef
8.
Zeng FA, Wilson A, Sheriff T, Murrell DF (2022) Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: a systematic review. JAAD international 9:33–43PubMedPubMedCentralCrossRef
9.
10.
Charneux J, Lorin J, Vitry F, Antonicelli F, Reguiai Z, Barbe C et al (2011) Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 147(3):286–291PubMedCrossRef
11.
Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P et al (2004) BP230-and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol 122(6):1413–1422PubMedCrossRef
12.
Yoshida M, Hamada T, Amagai M, Hashimoto K, Uehara R, Yamaguchi K et al (2006) Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 41(1):21–30PubMedCrossRef
13.
Delgado JC, Turbay D, Yunis EJ, Yunis JJ, Morton ED, Bhol K et al (1996) A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci 93(16):8569–8571PubMedPubMedCentralCrossRefADS
14.
Schiavo AL, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R (2013) Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol 31(4):391–399PubMedCrossRef
15.
Arakawa M, Dainichi T, Ishii N, Hamada T, Karashima T, Nakama T et al (2011) Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp Dermatol 20(12):1022–1024PubMedCrossRef
16.
17.
18.
19.
Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV (2019) New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol 10:1506PubMedPubMedCentralCrossRef
20.
21.
22.
23.
Messingham KA, Noe MH, Chapman MA, Giudice GJ, Fairley JA (2009) A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods 346(1–2):18–25PubMedPubMedCentralCrossRef
24.
Ishiura N, Fujimoto M, Watanabe R, Nakashima H, Kuwano Y, Yazawa N et al (2008) Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 49(2):153–161PubMedCrossRef
25.
Mihai S, Chiriac MT, Herrero-González JE, Goodall M, Jefferis R, Savage CO et al (2007) IgG4 autoantibodies induce dermal–epidermal separation. J Cell Mol Med 11(5):1117–1128PubMedPubMedCentralCrossRef
26.
27.
28.
29.
Asbrink E, Hovmark A (1984) Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies. Acta Derm Venereol 64(3):243–246PubMedCrossRef
30.
D’auria L, Pietravalle M, Mastroianni A, Ferraro C, Mussi A, Bonifati C et al (1998) IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch Dermatol Res 290(1–2):25–27PubMedCrossRef
31.
Ma L, Wang M, Wang X, Chen X, Zhu X (2015) Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients. J Dermatol Sci 78(1):76–77PubMedCrossRef
32.
33.
34.
35.
36.
37.
Karsten CM, Beckmann T, Holtsche MM, Tillmann J, Tofern S, Schulze FS et al (2018) Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2. Front Immunol 9:488PubMedPubMedCentralCrossRef
38.
Kushner CJ, Payne AS (2018) Increasing the complement of therapeutic options in bullous pemphigoid. J Invest Dermatol 138(2):246–248PubMedCrossRef
39.
Nunn M, Fettiplace J (2021) 25178 Disease remission during a short-term treatment phase II study of nomacopan in mild-to-moderate bullous pemphigoid. J Am Acad Dermatol 85(3):AB54
40.
41.
42.
Messingham KN, Wang JW, Holahan HM, Srikantha R, Aust SC, Fairley JA (2016) Eosinophil localization to the basement membrane zone is autoantibody-and complement-dependent in a human cryosection model of bullous pemphigoid. Exp Dermatol 25(1):50–55PubMedCrossRef
43.
Lin L, Hwang B-J, Culton DA, Li N, Burette S, Koller BH et al (2018) Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid. J Invest Dermatol 138(5):1032–1043PubMedCrossRef
44.
45.
46.
47.
48.
49.
50.
51.
52.
Majeski JA, Alexander JW (1977) Evaluation of tetracycline in the neutrophil chemotactic response. J Lab Clin Med 90(2):259–265PubMed
53.
Berk MA, Lorincz AL (1986) The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report Arch Dermatol 122(6):670–674PubMedCrossRef
54.
Khalid SN, Khan ZA, Ali MH, Almas T, Khedro T, Nagarajan VR (2021) A blistering new era for bullous pemphigoid: a scoping review of current therapies, ongoing clinical trials, and future directions. Annals of Medicine and Surgery 70:102799PubMedPubMedCentralCrossRef
55.
Tabatabaei-Panah P-S, Moravvej H, Alirajab M, Etaaty A, Geranmayeh M, Hosseine F et al (2022) Association between TH2 cytokine gene polymorphisms and risk of bullous pemphigoid. Immunol Invest 51(2):343–356PubMedCrossRef
56.
Kowalski EH, Kneibner D, Kridin K, Amber KT (2019) Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev 18(5):526–534PubMedCrossRef
57.
Abdelilah SG, Wellemans V, Agouli M, Guenounou M, Hamid Q, Beck LA et al (2006) Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. Clin Immunol 120(2):220–231
58.
Feliciani C, Toto P, Pour SM, Coscione G, Amerio P, Amerio P (1999) A Th2-like cytokine response is involved in bullous pemphigoid. the role of IL-4 and IL-5 in the pathogenesis of the disease. Int J Immunopathol Pharmacol 12(2):205873929901200202
59.
Giomi B, Caproni M, Calzolari A, Bianchi B, Fabbri P (2002) Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid. J Dermatol Sci 30(2):116–128PubMedCrossRef
60.
Wang Y, Mao X, Liu Y, Yang Y, Jin H, Li L (2022) IL-13 genetic susceptibility to bullous pemphigoid: a potential target for treatment and a prognostic marker. Front Immunol 13:51
61.
62.
63.
Chakievska L, Holtsche MM, Künstner A, Goletz S, Petersen B-S, Thaci D et al (2019) IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun 96:104–112PubMedCrossRef
64.
Riani M, Le Jan S, Plée J, Durlach A, Le Naour R, Haegeman G et al (2017) Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes. J Allergy Clin Immunol 139(3):863–872. e3
65.
Giusti D, Bini E, Terryn C, Didier K, Le Jan S, Gatouillat G et al (2019) NET formation in bullous pemphigoid patients with relapse is modulated by IL-17 and IL-23 interplay. Front Immunol 10:701PubMedPubMedCentralCrossRef
66.
Le Jan S, Muller C, Plee J, Durlach A, Bernard P, Antonicelli F (2019) IL-23/IL-17 axis activates IL-1beta-associated inflammasome in macrophages and generates an auto-inflammatory response in a subgroup of patients with bullous pemphigoid. Front Immunol 10:1972.https://​doi.​org/​10.​3389/​fimmu.​2019.​01972
67.
68.
Faurschou M, Borregaard N (2003) Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 5(14):1317–1327PubMedCrossRef
69.
Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P (1995) Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci 92(2):402–406PubMedPubMedCentralCrossRefADS
70.
Ståhle-Bäckdahl M, Inoue M, Guidice G, Parks W (1994) 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Investig 93(5):2022–2030PubMedPubMedCentralCrossRef
71.
72.
STOCKLEY RA (1999) Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 160(supplement_1):S49-S52
73.
Vergnolle N (2016) Protease inhibition as new therapeutic strategy for GI diseases. Gut 65(7):1215–1224PubMedCrossRef
74.
Korkmaz B, Horwitz MS, Jenne DE, Gauthier F (2010) Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 62(4):726–759PubMedPubMedCentralCrossRef
75.
Kobayashi SD, Voyich JM, Burlak C, DeLeo FR (2005) Neutrophils in the innate immune response. Arch Immunol Ther Exp (Warsz) 53(6):505–517PubMed
76.
77.
Oikarinen AI, Zone JJ, Ahmed AR, Kiistala U, Uitto J (1983) Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. J Invest Dermatol 81(3):261–6.https://​doi.​org/​10.​1111/​1523-1747.​ep12518285
78.
79.
80.
81.
82.
83.
Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA et al (2000) The serpin α1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102(5):647–655PubMedCrossRef
84.
85.
Niimi Y, Pawankar R, Kawana S (2006) Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol 139(2):104–113PubMedCrossRef
86.
Airola K, Reunala T, Salo S, Saarialho-Kere UK (1997) Urokinase plasminogen activator is expressed by basal keratinocytes before interstitial collagenase, stromelysin-1, and laminin-5 in experimentally induced dermatitis herpetiformis lesions. J Invest Dermatol 108(1):7–11PubMedCrossRef
87.
88.
Russo V, Klein T, Lim DJ, Solis N, Machado Y, Hiroyasu S et al (2018) Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction. Sci Rep 8(1):1–11CrossRef
89.
Afonina IS, Tynan GA, Logue SE, Cullen SP, Bots M, Lüthi AU et al (2011) Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell 44(2):265–278PubMedPubMedCentralCrossRef
90.
Perl M, Denk S, Kalbitz M, Huber-Lang M (2012) Granzyme B: a new crossroad of complement and apoptosis. Current Topics in Innate Immunity II:135–146
91.
Hiroyasu S, Zeglinski MR, Zhao H, Pawluk MA, Turner CT, Kasprick A et al (2021) Granzyme B inhibition reduces disease severity in autoimmune blistering diseases. Nat Commun 12(1):1–14CrossRef
92.
93.
Zebrowska A, Wagrowska-Danilewicz M, Danilewicz M, Wodz K, Sokolowska M, Erkiert-Polguj A et al (2009) Expression of selected ADAMs in bullous pemphigoid and dermatitis herpetiformis. J Dermatol Sci 56(1):58–61PubMedCrossRef
94.
Liu Y, Peng L, Li L, Liu C, Hu X, Xiao S et al (2017) TWEAK/Fn14 activation contributes to the pathogenesis of bullous pemphigoid. J Invest Dermatol 137(7):1512–1522PubMedCrossRef
95.
Shen S, Ke Y, Dang E, Fang H, Chang Y, Zhang J et al (2018) Semaphorin 4D from CD15+ granulocytes via ADAM10-induced cleavage contributes to antibody production in bullous pemphigoid. J Invest Dermatol 138(3):588–597PubMedCrossRef
96.
Winkles JA (2008) The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discovery 7(5):411–425PubMedCrossRef
97.
Liu Z-C, Zhou Q-L, Li X-Z, Yang J-H, Ao X, Zuo X-X (2011) Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Cytokine 53(3):295–300PubMedCrossRef
98.
99.
Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM (2017) JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77:521–546PubMedPubMedCentralCrossRef
100.
101.
Klein B, Treudler R, Simon JC. JAK‐inhibitors in dermatology–small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. JDDG: J  der Deutschen Dermatologischen Gesellschaft 20(1):19–24
102.
103.
Ferreira S, Guttman-Yassky E, Torres T (2020) Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol 21(6):783–798PubMedCrossRef
104.
Yasuda T, Fukada T, Nishida K, Nakayama M, Matsuda M, Miura I et al (2016) Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis. J Clin Investig 126(6):2064–2076PubMedPubMedCentralCrossRef
105.
Ashino S, Takeda K, Li H, Taylor V, Joetham A, Pine PR et al (2014) Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses. J Allergy Clin Immunol 133(4):1162–1174. e4
106.
107.
Heymann WR (2022) Immune checkpoint inhibitor-induced bullous pemphigoid quandaries. J Am Acad Dermatol 87(6):1285–1286PubMedCrossRef
108.
Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA dermatology
109.
Ernst N, Friedrich M, Bieber K, Kasperkiewicz M, Gross N, Sadik C et al (2021) Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris. J Eur Acad Dermatol Venereol 35(2):486–492PubMedCrossRef
110.
111.
Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R et al (2022) Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 36(10):1689–1704PubMedCrossRef
112.
Freire PC, Muñoz CH, Derhaschnig U, Schoergenhofer C, Firbas C, Parry GC et al (2019) Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid. J Invest Dermatol 139(12):2417–2424. e2
113.
Sadik CD, Rashid H, Hammers CM, Diercks GF, Weidinger A, Beissert S et al (2022) Evaluation of nomacopan for treatment of bullous pemphigoid: a phase 2a nonrandomized controlled trial. JAMA Dermatol 158(6):641–649PubMedPubMedCentralCrossRef
114.
Simon D, Yousefi S, Cazzaniga S, Bürgler C, Radonjic SI, Houriet C et al (2020) Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy 75(3):669–672PubMedCrossRef
115.
Baum STZ,  Baniel A, Sprecher E, Czernik A (2018) A pilot phase 2a study of the safety and efficacy of bertilimumab, an anti-eotaxin-1 antibody, in bullous pemphigoid. in: Editor (Ed.)^(Eds.). Book A Pilot Phase 2a Study of the Safety and Efficacy of Bertilimumab, an Anti-Eotaxin-1 Antibody, in Bullous Pemphigoid. Orlando, Florida
116.
Amber KT, Maglie R, Solimani F, Eming R, Hertl M (2018) Targeted therapies for autoimmune bullous diseases: current status. Drugs 78(15):1527–1548PubMedCrossRef
117.
118.
119.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S et al (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. The Lancet 389(10083):2031–2040CrossRef
120.
121.
Cho Y, Chu C, Wang L (2015) First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol 173(1):302–304PubMedCrossRef
122.
Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y, Feldman R (2019) Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol 81(1):179–186PubMedCrossRef
123.
Tovanabutra N, Payne AS (2020) Clinical outcome and safety of rituximab therapy for pemphigoid diseases. J Am Acad Dermatol 82(5):1237–1239PubMedCrossRef
124.
Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B (2018) Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol 9:248PubMedPubMedCentralCrossRef
125.
Ronaghy A, Streilein RD, Hall RP (2014) Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP). J Dermatol Sci 74(1):93–94PubMedCrossRef
126.
Ahmed AR, Shetty S, Kaveri S, Spigelman ZS (2016) Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up. J Am Acad Dermatol 74(4):700–708. e3
127.
Chee R, Nagendran V, Bansal A, Casie Chetty S, Harland C (2007) B-cell targeted therapy alone may not be effective in bullous pemphigoid. Clin Exp Dermatol 32(1):111–112PubMed
128.
Berkani N, Joly P, Golinski M-L, Colliou N, Lim A, Larbi A et al (2019) B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep 9(1):3525PubMedPubMedCentralCrossRefADS
129.
Schmidt E, Seitz C, Benoit S, Bröcker E, Goebeler M (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156(2):352–356PubMedCrossRef
130.
Russell Hall I, MD (2013) Rituximab in the Treatment of patients with bullous pemphigoid. in: Editor (Ed.)^(Eds.). Book Rituximab in the Treatment of Patients With Bullous Pemphigoid. ClinicalTrials.gov
131.
Kalled SL (2005) The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204(1):43–54PubMedCrossRef
132.
Dubey AK, Handu SS, Dubey S, Sharma P, Sharma K (2011) Belimumab: first targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother 2(4):317–319PubMedPubMedCentralCrossRef
133.
Petricca L, Gigante MR, Paglionico A, Costanzi S, Vischini G, Di Mario C et al (2020) Rituximab followed by belimumab controls severe lupus nephritis and bullous pemphigoid in systemic lupus erythematosus refractory to several combination therapies. Front Med 7:553075CrossRef
134.
Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C (2005) The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115(3):459–465PubMedCrossRef
135.
136.
137.
Deza G, Ricketti PA, Giménez-Arnau AM, Casale TB (2018) Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria. The Journal of Allergy and Clinical Immunology: In Practice 6(4):1108–1117
138.
Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60(3):309–316PubMedCrossRef
139.
Gönül M, Keseroglu HO, Ergin C, Özcan I, Erdem Ö (2016) Bullous pemphigoid successfully treated with omalizumab. Indian J Dermatol Venereol Leprol 82:577PubMedCrossRef
140.
Kenneth KY, Crew AB, Messingham KA, Fairley JA, Woodley DT (2014) Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 71(3):468–474CrossRef
141.
Vassallo C, Somenzi A, De Amici M, Barruscotti S, Brazzelli V (2022) Omalizumab as a corticosteroid‐sparing agent in the treatment of bullous pemphigoid. Dermatol Ther e15946
142.
Seyed Jafari SM, Gadaldi K, Feldmeyer L, Yawalkar N, Borradori L, Schlapbach C (2019) Effects of omalizumab on FcεRI and IgE expression in lesional skin of bullous pemphigoid. Front Immunol 10:1919PubMedPubMedCentralCrossRef
143.
Uysal PI, Yalcin B, Oktem A (2017) Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid. Turkderm Turk Arch Drematol Venereol 51:124–128
144.
Cao P, Xu W, Zhang L (2022) Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol 13:928621
145.
146.
Goebl NA, Babbey CM, Datta-Mannan A, Witcher DR, Wroblewski VJ, Dunn KW (2008) Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 19(12):5490–5505PubMedPubMedCentralCrossRef
147.
Zakrzewicz A, Würth C, Beckert B, Feldhoff S, Vanderheyden K, Foss S et al (2022) Stabilization of keratinocyte monolayer integrity in the presence of anti-desmoglein-3 antibodies through FcRn blockade with efgartigimod: novel treatment paradigm for pemphigus? Cells 11(6):942PubMedPubMedCentralCrossRef
148.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet Neurology 20(7):526–536PubMedCrossRef
149.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H et al (2022) Efficacy and safety of intravenous efgartigimod in adults with primary immune thrombocytopenia: results of a phase 3, multicenter, double-blinded, placebo-controlled, randomized clinical trial (ADVANCE IV). Blood 140(Supplement 1):6–8. https://​doi.​org/​10.​1182/​blood-2022-167838CrossRef
150.
Guptill J, Antozzi C, Bril V, Gamez J, Meuth SG, Blanco JLM et al (2021) Vivacity-MG: a phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of nipocalimab administered to adults with generalized myasthenia gravis (2157). in: Editor (Ed.)^(Eds.). Book Vivacity-MG: a phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of nipocalimab administered to adults with generalized myasthenia gravis (2157). AAN Enterprises
151.
Gál P, Ambrus G, Závodszky P (2002) C1s, the protease messenger of C1. Immunobiology 205(4–5):383–394PubMedCrossRef
152.
153.
Heimbach L, Li Z, Berkowitz P, Zhao M, Li N, Rubenstein DS et al (2011) The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid. J Biol Chem 286(17):15003–15009PubMedPubMedCentralCrossRef
154.
155.
Maurer M, Khan DA, Komi DEA, Kaplan AP (2021) Biologics for the use in chronic spontaneous urticaria: when and which. The Journal of Allergy and Clinical Immunology: In Practice 9(3):1067–1078
156.
Carvelli J, Meziani F, Dellamonica J, Cordier P-Y, Allardet-Servent J, Fraisse M et al (2022) Avdoralimab (anti-C5aR1 mAb) versus placebo in patients with severe COVID-19: results from a randomized controlled trial (FOR COVID Elimination [FORCE]). Crit Care Med 50(12):1788–1798PubMedPubMedCentralCrossRef
157.
Wagner F, Lange C, Nowak M, Ignatenko S (2014) FRI0315 first human dose of the anti-C5a receptor-targeting, human monoclonal antibody NNC0215-0384 in patients with rheumatoid arthritis: a phase 1, randomised, double-blind, single-dose, dose-escalation trial. Ann Rheum Dis 73(Suppl 2):499–499CrossRef
158.
Hepburn NJ, Williams AS, Nunn MA, Chamberlain-Banoub JC, Hamer J, Morgan BP et al (2007) In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem 282(11):8292–8299PubMedCrossRef
159.
Jore MM, Johnson S, Sheppard D, Barber NM, Li YI, Nunn MA et al (2016) Structural basis for therapeutic inhibition of complement C5. Nat Struct Mol Biol 23(5):378–386PubMedPubMedCentralCrossRef
160.
Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM et al (2019) Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI insight 4(15)
161.
Sezin T, Krajewski M, Wutkowski A, Mousavi S, Chakievska L, Bieber K et al (2017) The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita. J Invest Dermatol 137(5):1104–1113PubMedCrossRef
162.
Akari Therapeutics receives FDA Fast track designation for nomacopan for the treatment of bullous pemphigoid. in: Editor (Ed.)^(Eds.). Book Akari Therapeutics receives FDA fast track designation for nomacopan for the treatment of bullous pemphigoid. Akari Therapeutics. 2021. pp
163.
Yamamoto H, Fara AF, Dasgupta P, Kemper C (2013) CD46: the ‘multitasker’of complement proteins. Int J Biochem Cell Biol 45(12):2808–2820PubMedCrossRef
164.
Qiao P, Luo Y-X, Zhi D-L, Wang G, Dang E-L (2021) Blockade of complement activation in bullous pemphigoid by using recombinant CD55-CD46 fusion protein. Chin Med J 134(07):864–866PubMedCrossRef
165.
Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW (2001) Th2 cytokines and asthma the role of interleukin-5 in allergic eosinophilic disease. Respir Res 2(2):1–9CrossRef
166.
D’Auria L, Pietravalle M, Mastroianni A, Ferraro C, Mussi A, Bonifati C et al (1998) IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch Dermatol Res 290(1–2):25–27. https://​doi.​org/​10.​1007/​s004030050272CrossRefPubMed
167.
Hom S, Pisano M (2017) Reslizumab (Cinqair): an interleukin-5 antagonist for severe asthma of the eosinophilic phenotype. Pharmacy and Therapeutics 42(9):564PubMedPubMedCentral
168.
Rhyou H-I, Han S-H, Nam Y-H (2021) Successful induction treatment of bullous pemphigoid using reslizumab: a case report. Allergy Asthma Clin Immunol 17(1):1–4CrossRef
169.
Ghazi A, Trikha A, Calhoun WJ (2012) Benralizumab–a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity–a novel approach for the treatment of asthma. Expert Opin Biol Ther 12(1):113–118PubMedCrossRef
170.
Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM et al (2010) MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125(6):1344–1353. e2
171.
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M et al (2016) Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 388(10056):2128–2141CrossRef
172.
Kagami S, Kai H, Kakinuma T, Miyagaki T, Kamata M, Sugaya M (2012) High levels of CCL26 in blister fluid and sera of patients with bullous pemphigoid. J Invest Dermatol 132(1):249–251PubMedCrossRef
173.
Bertilimumab granted fast track designation for the treatment of bullous pemphigoid. in: Editor (Ed.)^(Eds.). Book Bertilimumab granted fast track designation for the treatment of bullous pemphigoid. GlobeNewswire, Inc. Clinical Leader. 2018. pp
174.
Egami S, Yamagami J, Amagai M (2020) Autoimmune bullous skin diseases, pemphigus and pemphigoid. J Allergy Clin Immunol 145(4):1031–1047PubMedCrossRef
175.
Samanta A, Aziz AA, Jhingan M, Singh SR, Khanani A, Chhablani J (2020) Emerging therapies in neovascular age-related macular degeneration in 2020. Asia-Pacific journal of ophthalmology (Philadelphia, Pa) 9(3):250PubMedCrossRef
176.
Norling LV, Perretti M, Cooper D (2009) Endogenous galectins and the control of the host inflammatory response. J Endocrinol 201(2):169–184PubMedCrossRef
177.
Katoh S, Nobumoto A, Matsumoto N, Matsumoto K, Ehara N, Niki T et al (2010) Involvement of galectin-9 in lung eosinophilia in patients with eosinophilic pneumonia. Int Arch Allergy Immunol 153(3):294–302PubMedCrossRef
178.
Chihara M, Kurita M, Yoshihara Y, Asahina A, Yanaba K (2018) Clinical significance of serum galectin-9 and soluble CD155 levels in patients with systemic sclerosis. J Immunol Res 2018
179.
Nakajima R, Miyagaki T, Oka T, Nakao M, Kawaguchi M, Suga H et al (2015) Elevated serum galectin-9 levels in patients with atopic dermatitis. J Dermatol 42(7):723–726PubMedCrossRef
180.
Wiersma VR, Clarke A, Pouwels SD, Perry E, Abdullah TM, Kelly C et al (2019) Galectin-9 is a possible promoter of immunopathology in rheumatoid arthritis by activation of peptidyl arginine deiminase 4 (PAD-4) in granulocytes. Int J Mol Sci 20(16):4046PubMedPubMedCentralCrossRef
181.
Yang R, Sun L, Li C-F, Wang Y-H, Yao J, Li H et al (2021) Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun 12(1):832PubMedPubMedCentralCrossRefADS
182.
Pruessmann J, Pruessmann W, Holtsche MM, Linnemann B, Hammers CM, van Beek N et al (2021) Immunomodulator galectin-9 is increased in blood and skin of patients with bullous pemphigoid. Acta Derm Venereol 101(3):adv00419-adv00419
183.
Barker J, Jones M, Mitra R, Crockett-Torabe E, Fantone J, Kunkel SL et al (1991) Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 139(4):869PubMedPubMedCentral
184.
Messingham KN, Srikantha R, DeGueme AM, Fairley JA (2011) FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid. J Immunol 187(1):553–560PubMedCrossRef
185.
Inaoki M, Takehara K (1998) Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid. J Dermatol Sci 16(2):152–157PubMedCrossRef
186.
Bertini R, Barcelos L, Beccari A, Cavalieri B, Moriconi A, Bizzarri C et al (2012) Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. Br J Pharmacol 165(2):436–454PubMedPubMedCentralCrossRef
187.
188.
189.
190.
Hoter A, El-Sabban ME, Naim HY (2018) The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci 19(9):2560PubMedPubMedCentralCrossRef
191.
Tukaj S, Kleszczyński K, Vafia K, Groth S, Meyersburg D, Trzonkowski P et al (2013) Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid. Plos One 8(7):e70496PubMedPubMedCentralCrossRefADS
192.
193.
Nizami S, Arunasalam K, Green J, Cook J, Lawrence CB, Zarganes-Tzitzikas T et al (2021) Inhibition of the NLRP3 inflammasome by HSP90 inhibitors. Immunology 162(1):84–91PubMedCrossRef
194.
Tukaj S, Zillikens D, Kasperkiewicz M (2015) Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases. Exp Dermatol 24(8):567–571PubMedCrossRef
195.
Tukaj S, Sitko K (2022) Heat shock protein 90 (Hsp90) and Hsp70 as potential therapeutic targets in autoimmune skin diseases. Biomolecules 12(8):1153PubMedPubMedCentralCrossRef
196.
197.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348PubMedCrossRef
198.
Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D (2018) Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol 154(10):1225–1226PubMedCrossRef
199.
Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B et al (2020) Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol 83(1):46–52PubMedCrossRef
200.
Zhang Y, Zhang J, Chen J, Xu Q, Zou Y, Chao J (2021) Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid. Front Immunol 4144
201.
Seyed Jafari SM, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L (2021) Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid. Front Immunol 11:611549PubMedPubMedCentralCrossRef
202.
203.
Shipman WD, Singh K, Cohen JM, Leventhal J, Damsky W, Tomayko MM (2023) Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. Br J Dermatol 189(3):339–341PubMedCrossRef
204.
Zhang L, Chen Z, Wang L, Luo X (2023) Bullous pemphigoid: the role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol 14:1115083PubMedPubMedCentralCrossRef
205.
206.
Friend SL, Hosier S, Nelson A, Foxworthe D, Williams D, Farr A (1994) A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. Exp Hematol 22(3):321–328PubMed
207.
208.
Li S-Z, Jin X-X, Ge X-L, Zuo Y-G, Jin H-Z (2020) Thymic stromal lymphopoietin is implicated in the pathogenesis of bullous pemphigoid by dendritic cells. J Immunol Res 2020
209.
Zhang Y, Hwang B-J, Liu Z, Li N, Lough K, Williams SE et al (2018) BP180 dysfunction triggers spontaneous skin inflammation in mice. Proc Natl Acad Sci 115(25):6434–6439PubMedPubMedCentralCrossRefADS
210.
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME et al (2021) Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 384(19):1800–1809PubMedCrossRef
211.
Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M et al (2019) Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol 80(4):1013–1021PubMedCrossRef
212.
Prieto-Peña D, Dasgupta B (2020) Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. Pol Arch Intern Med 131:171–181PubMed
213.
Mangold A (2019) Ixekizumab in the treatment of bullous pemphigoid. in: Editor (Ed.)^(Eds.). Book Ixekizumab in the treatment of bullous pemphigoid. ClinicalTrials.gov
214.
215.
216.
Holtsche MM, Hammers CM, Chakievska L, Ludwig RJ, Thaci D, Zillikens D et al (2020) Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 18(12):1478–1480
217.
Kamata M, Asano Y, Shida R, Maeda N, Yoshizaki A, Miyagaki T et al (2019) Secukinumab decreased circulating anti-BP 180-NC 16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid. J Dermatol 46(6):e216–e217PubMedCrossRef
218.
Yun JS, Scardamaglia L, Tan CG, McCormack CJ (2022) Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report. Australas J Dermatol
219.
Maronese CA, Cassano N, Genovese G, Foti C, Vena GA, Marzano AV (2022) The intriguing links between psoriasis and bullous pemphigoid. J Clin Med 12(1):328PubMedPubMedCentralCrossRef
220.
Schurich A, Raine C, Morris V, Ciurtin C (2018) The role of IL-12/23 in T cell–related chronic inflammation: implications of immunodeficiency and therapeutic blockade. Rheumatology 57(2):246–254PubMedCrossRef
221.
Majima Y, Yagi H, Tateishi C, Groth S, Schmidt E, Zillikens D et al (2013) A successful treatment with ustekinumab in a case of antilaminin-γ1 pemphigoid associated with psoriasis. Br J Dermatol 168(6):1367–1369PubMedCrossRef
222.
Loget F, Plée P, Antonicelli F, Bernard P, Loget J, Plée J (2017) A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol 31(5):e228–e230PubMedCrossRef
223.
Querol‐Cisneros E, Moreno‐Artero E, Rodríguez‐Garijo N, Tomás‐Velázquez A, Querol I, Ishii N et al (2021) Bullous pemphigoid without detection of autoantibodies in a patient with psoriasis under ustekinumab. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 19(2):265–267
224.
Le Guern A, Alkeraye S, Vermersch-Langlin A, Coupe P, Vonarx M (2015) Bullous pemphigoid during ustekinumab therapy. JAAD Case Reports 1(6):359–360PubMedPubMedCentralCrossRef
225.
Onsun N, Sallahoglu K, Dizman D, Su Ö, Tosuner Z (2017) Bullous pemphigoid during ustekinumab therapy in a psoriatic patient. Eur J Dermatol 27(1):81–82PubMedCrossRef
226.
Marin M, Alzueta N, Castresana M, Gascón A, Pío M (2021) Bullous pemphigoid induced by ustekinumab: a case report. Eur J Hosp Pharm 28(1):47–49PubMedCrossRef
227.
228.
229.
230.
Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J et al (2013) Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin Ther 35(8):1137–1149PubMedCrossRef
231.
232.
Yu X, Akbarzadeh R, Pieper M, Scholzen T, Gehrig S, Schultz C et al (2018) Neutrophil adhesion is a prerequisite for antibody-mediated proteolytic tissue damage in experimental models of epidermolysis bullosa acquisita. J Invest Dermatol 138(9):1990–1998PubMedCrossRef
233.
Ogut D, Reel B, Korkmaz CG, Arun MZ, Micili SC, Ergur BU (2016) Doxycycline down-regulates matrix metalloproteinase expression and inhibits NF-κB signaling in LPS-induced PC3 cells. Folia Histochem Cytobiol 54(4):171–180PubMedCrossRef
234.
Stechmiller J, Cowan L, Schultz G (2010) The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds. Biol Res Nurs 11(4):336–344PubMedCrossRef
235.
Jung J-J, Razavian M, Kim H-Y, Ye Y, Golestani R, Toczek J et al (2016) Matrix metalloproteinase inhibitor, doxycycline and progression of calcific aortic valve disease in hyperlipidemic mice. Sci Rep 6(1):32659PubMedPubMedCentralCrossRefADS
236.
Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E et al (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. The Lancet 389(10079):1630–1638CrossRef
237.
Vandenbroucke RE, Libert C (2014) Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discovery 13(12):904–927PubMedCrossRef
238.
Dufour A, Overall CM (2013) Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci 34(4):233–242PubMedCrossRef
239.
Shi Y, Ma X, Fang G, Tian X, Ge C (2021) Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: recent progress and current challenges. NanoImpact 21:100293PubMedCrossRef
240.
Werny L, Grogro A, Bickenbach K, Bülck C, Armbrust F, Koudelka T et al (2023) MT1-MMP and ADAM10/17 exhibit a remarkable overlap of shedding properties. FEBS J 290(1):93–111PubMedCrossRef
241.
Dreymueller D, Ludwig A (2017) Considerations on inhibition approaches for proinflammatory functions of ADAM proteases. Platelets 28(4):354–361PubMedCrossRef
242.
Kataoka H (2009) EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J Dermatol Sci 56(3):148–153PubMedCrossRef
243.
244.
Sarny S, Hucke M, El-Shabrawi Y (2018) Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib. JAMA ophthalmology 136(12):1420–1422PubMedCrossRef
245.
James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA (2021) Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep 22:101104
246.
Xiao Y, Xiang H, Li W (2022) Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor baricitinib. Dermatol Ther 35(10):e15754PubMedCrossRef
247.
MacFarlane L-A, R Murphy P (2010) MicroRNA: biogenesis, function and role in cancer. Current genomics 11(7):537–561
248.
Chen J-Q, Papp G, Szodoray P, Zeher M (2016) The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmun Rev 15(12):1171–1180PubMedCrossRef
249.
250.
GÖKŞİN ŞS, URGANCI BE, İMREN IG, AÇIKBAŞ İ (2022) Comparison of serum and lesional miRNA-1291 expressions in patients with bullous pemphigoid. Pamukkale Med J 15(4):22–22
251.
Qiu L, Zhang L, Qi R, Gao X, Chen H, Xiao T (2020) miR-1291 functions as a potential serum biomarker for bullous pemphigoid. Dis Markers 2020
252.
Papara C, Zillikens D, Sadik CD, Baican A (2021) MicroRNAs in pemphigus and pemphigoid diseases. Autoimmun Rev 20(7):102852PubMedCrossRef
253.
254.
Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N (2019) CAR T cell therapy: a new era for cancer treatment. Oncol Rep 42(6):2183–2195PubMed
255.
Grigor EJ, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD et al (2019) Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev 33(2):98–110PubMedCrossRef
256.
Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):1–11MathSciNetCrossRef
257.
Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ et al (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353(6295):179–184PubMedPubMedCentralCrossRefADS
258.
Lee J, Lundgren DK, Mao X, Manfredo-Vieira S, Nunez-Cruz S, Williams EF et al (2020) Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Investig 130(12):6317–6324PubMedPubMedCentralCrossRef
259.
David J. Chang SB, Gwendolyn K. Binder (2022) A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris patients: preliminary data. in: Editor (Ed.)^(Eds.). Book A Phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris patients: preliminary data. Milan
260.
Bieber K, Kridin K, Emtenani S, Boch K, Schmidt E, Ludwig RJ (2021) Milestones in personalized medicine in pemphigus and pemphigoid. Front Immunol 11:591971PubMedPubMedCentralCrossRef
261.
Bieber K, Ludwig RJ (2020) Drug development in pemphigoid diseases. Acta Derm Venereol 100(5):108–114CrossRef
Metadaten
Titel
Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches
verfasst von
Hsuan-Chi Chen
Chuang-Wei Wang
Wu Han Toh
Hua-En Lee
Wen-Hung Chung
Chun-Bing Chen
Publikationsdatum
28.10.2023
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 3/2023
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-023-08973-1

Weitere Artikel der Ausgabe 3/2023

Clinical Reviews in Allergy & Immunology 3/2023 Zur Ausgabe

Research

A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency—Real-World Data

Review

Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis

Review

Autoinflammatory Keratinization Diseases—The Concept, Pathophysiology, and Clinical Implications

Review

A Comprehensive Review of Sulfonamide Hypersensitivity: Implications for Clinical Practice

Review

Eosinophil-Associated Gastrointestinal Manifestations During OIT

Review

Diverse Endotypes of Chronic Rhinosinusitis and Clinical Implications

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise